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The CC chemokine ligand 18 (CCL18) was first identified as a chemoattractant for naïve
T cells. It has been reported to recruit T and B lymphocytes, and we show here, natural
killer (NK) cells, but with low efficacy. Investigation of its ability to elicit G-protein-coupled
signaling showed that it does not involve extracellular signal-regulated kinase (ERK) phos-
phorylation, and it is not able to induce receptor internalization, as assessed on CCR3.
CCL18 has recently been reported to possess activities unrelated to cellular recruitment,
but it had no effect on T lymphocyte proliferation. We postulated that a more potent
chemoattractant may be produced under inflammatory conditions but only minor trun-
cations were observed, with the major form being the full-length protein. In view of the
lack of potent immunomodulatory properties, we wondered if binding to CCL18 by the
tick chemokine binding proteins Evasin-1 and -4 was an artifact of the methods used, but
complex formation was confirmed by size exclusion chromatography, and abrogation of its
binding to, and antagonism of, CCR3. Its receptor has remained elusive since its cloning in
1997, although it has been reported to induce migration of breast cancer cells by signaling
through PITPNM3, but we show that this receptor is not expressed on lymphocytes. We
have developed a radiolabeled equilibrium competition binding assay and demonstrated
that it bound with high affinity to peripheral blood leukocytes (PBLs), but the binding was
displaced similarly by both unlabelled CCL18 as well as heparin. Both heparin binding and
binding to PBLs are considerably abrogated by mutation of the BBXB motif in the 40s loop
suggesting an essential role of the CCL18-glycosaminoglycan interaction.
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INTRODUCTION
Chemokines are cytokines with selective chemotactic proper-
ties. They coordinate leukocyte migration during immunity and
inflammation and are also involved in the pathogenesis of sev-
eral human diseases. The family consists of approximately 50
chemokines which trigger their biological responses by activat-
ing seven-transmembrane domain G-protein-coupled receptors
(7TM GPCRs) on their target cells, 20 of which have been iden-
tified to date. By definition leukocyte chemoattraction is the hall-
mark function of chemokines, however chemokines also induce
cellular responses that are unrelated to leukocyte migration such as
cell differentiation and activation (1), apoptosis (2), development
(3), angiogenesis (4), or tumor growth and metastasis (5, 6).
Two chemokines remain orphan in that their receptor has
not yet been identified: CCL18 and CXCL14. CCL18 has been
described to mediate various functions such as chemotaxis
mediated by G-protein coupling, intracellular calcium mobiliza-
tion, and actin polymerization, however its classical, signaling
chemokine receptor(s), presumably a 7TM GPCR, remains elu-
sive. It has, however, been reported to bind and antagonize
CCR3 (7). Recently PITPNM3 was described to be a functional
receptor for CCL18 (8). PITPNM3, which is also known as
PYK2 N-terminal domain-interacting receptor 1 (Nir1), belongs
to the phosphatidylinositol transfer protein (PITP) membrane-
associated subfamily. PITPNM3/Nir1 was shown to be expressed
in human retina, brain, spleen as well as ovary and recently it was
also shown to be abundantly expressed in breast cancer cells (8,
9). CCL18 produced by breast tumor-associated macrophages was
shown to be involved in breast cancer metastasis via the interaction
and signaling through PITPNM3/Nir1, which was pertussis toxin
(PTX) dependent, despite the fact that PITPNM3/Nir1 does not
show apparent structural or functional similarity to conventional
GPCRs (8).
We describe here chemotaxis induced by CCL18 on T lympho-
cytes as previously reported (10–12) as well as B lymphocytes (13)
and show it also attracts natural killer (NK) cells. The response,
which is particularly weak, is however PTX dependent, which
points to the involvement of Gαi proteins and G-protein-coupled
receptors.
Post-translational modifications of chemokines have been well
described and have been shown to modulate chemokine activity
with either no effect or decreased or increased activity, as well
as altered receptor specificity (reviewed in 14). Modifications at
the amino-terminus (N-terminus) of the chemokine have the
greatest impact on biological activity and selectivity, due to the
involvement of this region in the interaction with its receptor(s).
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Certain chemokines have been shown to be converted into potent
chemoattractants by proteases, which are released during inflam-
matory responses (15). For example CCL5 is more potent in induc-
ing CCR5 mediated responses when converted to 3–68, although
this form becomes an antagonist on CCR1 (14). Importantly, low
affinity ligands for CCR1, which are abundant in the circula-
tion, are converted into high affinity ligands by processing at the
N-terminus (14). In fact isolation of natural CCL18 from the con-
ditioned medium of peripheral blood mononuclear cells (PBMCs)
demonstrated variants lacking two or three N-terminal amino acid
residues in addition to the intact full length CCL18 (16).
We have addressed several questions concerning the biolog-
ical role of CCL18. We looked for a more potent form in the
circulation under inflammatory conditions. Despite the fact that
the chemoattractant properties of CCL18 are unimpressive, we
addressed the question of whether the Evasins, chemokine binding
proteins (CkBPs) produced by the tick Rhipicephalus sanguineus,
really do bind CCL18. We also investigated whether the trans-
membrane receptor that mediates breast cancer cell metastasis is
the elusive CCL18 receptor. Lastly, we considered attempting to
identify the CCL18 receptor by expression cloning from responsive
cells, but analysis of its binding to the surface of PBLs revealed that
the major binding interaction is to glycosaminoglycans (GAGs).
MATERIALS AND METHODS
REAGENTS
Chemokines were obtained from PeptroTech or produced as pre-
viously described (17). Polyclonal anti-CCL18 antibodies were
obtained from R&D systems. Radiolabeled CCL18 (125I-CCL18)
was obtained from Anawa. Evasin-1, -3, and -4 were produced as
previously described (18, 19).
CHEMOTAXIS ASSAYS
Chemotaxis assays were carried out as previously described (20).
Lymphocyte subpopulations (CD4+ T lymphocytes, CD8+ T lym-
phocytes, B lymphocytes, and NK cells) were purified from human
blood by density gradient centrifugation through Ficoll followed
by negative selection using a MACS Isolation kit (Miltenyi Biotec)
following the manufacturer’s instructions. Twenty microliters of
the cell solutions was deposited on top of the membrane of each
well (75× 103 CD4+ and CD8+ T lymphocytes and NK cells and
50× 103 B lymphocytes). The chambers were incubated for 1 h.
CHEMOTAXIS ASSAY WITH PTX-TREATED PBL
Peripheral blood leukocyte were purified by Ficoll gradient cen-
trifugation (Ficoll-Paque PLUS, GE Healthcare) and separated
from the monocytes by allowing them to adhere to tissue culture
plastic in RPMI 1640 containing 10% Fetal Calf serum (FCS),
5 mM l-Glutamine, and 50 U/ml Penicillin/Streptomycin (P/S)
for 120 min at 37°C. Fifty micrograms of PTX were suspended in
500µl sterile ddH2O containing 2.5 mg/ml Bovine serum albumin
(BSA) (100µg/ml). Cells (30× 105) were suspended in RPMI 1640
complete medium containing 200 ng/ml PTX and incubated for
2 h in a 5% CO2 humidified incubator at 37°C. The PTX-treated
cells were washed twice in chemotaxis medium and chemotaxis
assays were performed as described above.
ERK-1/2 PHOSPHORYLATION
The experiment was performed as previously described (21) using
T lymphocytes, which were purified from human blood by density
gradient centrifugation through Ficoll followed by negative selec-
tion using a MACS Isolation kit (Miltenyi Biotec) following the
manufacturer’s instructions.
CCR3 LIGAND-INDUCED INTERNALIZATION IN EOSINOPHILS
Eosinophils were purified from human blood by negative
immunomagnetic selection as previously reported (22) using the
human Eosinophil Enrichment Kit (Easy Sep) following the man-
ufacturer’s instructions. The cells were suspended in RPMI 1640
supplemented with 10% FCS, 5 mM l-Glutamine, and 50 U/ml
P/S and stored overnight at 4°C. Eosinophils were exposed to 12.5
or 125 nM of CCL18 or 12.5 nM CCL5 and CCL11 for 15 min or
1 h as previously described (22). Cells were incubated with 1µg
anti-human CCR3 antibody (clone 5E8, BD Pharmingen) or iso-
type control (Alexa Fluor 647 Mouse IgG2b, gamma) and CCR3
expression analyzed by flow cytometry.
CELL PROLIFERATION ASSAY
Cellular proliferation was assessed using carboxyfluorescein diac-
etate succinimidyl ester (CFSE) and analyzed by flow cytometry
as previously described (23). T lymphocytes were incubated with
CFSE at a final concentration of 5µM for 5 min at 37°C. The
reaction was stopped by adding RPMI 1640 complete medium.
CCL18 (1 nM, 10 nM, 100 nM, or 1µM) was added to the cells 1 h
before cell stimulation. After the pre-incubation period, cells were
transferred to 96-well plates pre-coated with 5µg/ml plate bound
anti-CD3 (BD Pharmingen) in the presence of soluble anti-CD28
antibodies (10µg/ml) (BD Pharmingen). In parallel the assay was
performed without anti-CD3/CD28 stimulation.
GENERATION OF∆2- AND∆3-CCL18-6HIS AND 44AAGA47-CCL18
Mutagenesis was performed by Polymerase chain reaction (PCR)
using a pEAK12d plasmid containing the sequence of CCL18-
6His as template. The deletions of the N-terminal amino acids
were made using site directed mutagenesis with the mutagen-
esis primer: ∆2-CCL18-6His_forward 5′-GCC CTC TGC TCC
TGT GTT GGT ACC AAC AAA G and ∆2-CCL18-6His_reverse
5-CTT TGT TGG TAC CAA CAC AGG AGC AGA GGG C as well
as ∆3-CCL18-6His_forward 5′-GGC CCT CTG CTC CTG TGG
TAC CAA CAA AGA GC and ∆3-CCL18-6His_reverse 5′-GCT
CTT TGT TGG TAC CAC AGG AGC AGA GGG CAA TG. The
mutations of K44, R45, and R47 to alanine residues were per-
formed using the primers: 44AAGA47_forward 5′-CCT CCT AAC
CGC CGC CGG CGC CCA GAT CTG TGC TGA CCC C and
44AAGA47_reverse 5′-GGG GTC AGC ACA GAT CTG GGC GCC
GGC GGC GGT TAG GAG G. The mutations were introduced
in a one step PCR reaction followed by a Dpn1 digestion of the
parental plasmid DNA.
PROTEIN PURIFICATION AND CHARACTERIZATION
The mutant plasmids were transformed into HEK293-6E cells.
Eight hundred milliliters of FreeStyle F17 Expression Medium sup-
plemented with 4 mM l-Glutamine and 10 ml/l of 10% Pluronic
F68 (final concentration 0.1%) were inoculated with HEK293-
6E cells and grown in a shake flask on an orbital shaker at
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80 rpm until a cell density between 1.5 and 2.0× 106 cells/ml
was reached. Cells were transfected with 2 mg/l PEI and 1 mg/l
plasmid. Cells were incubated at 37°C in a humidified incuba-
tor containing 5% CO2 for 5 days. The culture supernatant was
harvested by centrifugation for 15 min at 3500× g and filtered
using 0.22µm membrane filter device. The solution was adjusted
to a pH between 7.0 and 7.2 and the solution was applied to
an SP Sepharose column (XK50/4.6) previously equilibrated in
10 mM Tris/HCl, pH 7.0. Proteins were eluted with 1 M NaCl in
50 mM NaPO4, pH 7.3. The fractions containing the CCL18 pro-
teins were pooled and applied to a POROS 20 MC metal chelate
affinity column, which had previously been loaded with Ni2+
ions using a 100-mM Ni(II)SO4 solution and equilibrated with
50 mM NaH2PO4, 600 mM NaCl, 8.7% (vol/vol) glycerol, pH 7.5.
∆2-CCL18-6His, ∆3-CCL18-6His, and 44AAGA47-CCL18-6His
were eluted by 50 mM NaH2PO4, 600 mM NaCl, 8.7% glyc-
erol, 400 mM imidazole, pH 7.5. Protein containing fractions
were loaded onto a Superdex 75 column (XK 16/60), which was
previously equilibrated with PBS at a flow rate of 1.5 ml/min.
EQUILIBRIUM COMPETITION BINDING ASSAY
Binding assays were performed using PBL purified as described
above. Cells were suspended at a density of 4× 106 cells/ml in
binding buffer (50 mM Tris/HCl pH 7.5 buffer containing 1 mM
CaCl2, 5 mM MgCl2, and 0.5% BSA) to be used at a final con-
centration of 0.1× 106 cells/well. 125I-chemokine was dissolved
at 0.4 nM in binding buffer to reach 0.1 nM final concentration.
Dilutions of CCL18 proteins were prepared by fourfold dilutions
to cover a range from 10−6 to 10−12 M. The assay was performed
in triplicate. The mixture of cells, chemokine, 125I-chemokine,
and binding buffer was incubated for 4 h at room temperature
(RT) under gentle agitation. Cells were then washed three times
with 200µl wash buffer (50 mM Tris/HCl pH 7.5 buffer contain-
ing 1 mM CaCl2, 5 mM MgCl2, 0.5% BSA, and 0.5 M NaCl) using
vacuum filtration. Finally 50µl of scintillation liquid was added
to each well and the radioactivity measured using a β-scintillation
counter. Binding assays were performed using the MultiScreen
HTS 96-well filtration system.
SURFACE ENHANCED LASER DESORPTION/IONIZATION TIME OF
FLIGHT MASS SPECTROMETRY
The surface enhanced laser desorption/ionization time of flight
mass spectrometry (SELDI-TOF MS) platform was used in order
to capture CCL18 on anti-CCL18 polyclonal antibody coated
chips, which enables the analysis of biological samples unrelated to
the complexity of the sample. Initially analysis of the integrity of
CCL18 on the NP20 ProteinChip was first determined by applying
CCL18 (5µl at a concentration of 1 mg/ml) onto a NP20 Pro-
teinChip Array (BioRad) as previously described (24). A saturated
solution of sinapinic acid in 50% acetonitrile containing 1% Tri-
fluoroacetic acid (TFA) in distilled H2O was added onto each spot
and air-dried. Mass analyses were performed by SELDI-TOF MS
using the ProteinChip Biology System II and the Ciphergen pro-
tein chip software version 3.2.1. Mass spectra were generated with
a mass focus between 0 and 15 kDa. To determine the detection
limit of CCL18 by SELDI-TOF MS a dilution series of recombi-
nant CCL18 (0.15–10 ng final amount) in PBS, containing 0.1%
Triton-X-100 was applied onto an anti-CCL18 polyclonal antibody
coated RS100 ProteinChip Array (BioRad Laboratories) as previ-
ously described (24). A saturated solution of sinapinic acid in 50%
acetonitrile containing 1% TFA in distilled H2O was added onto
each spot, air-dried, and mass analysis were performed using the
conditions as described above. For the detection of the chemokine
in the synovial fluid RS100 ProteinChips coated with polyclonal
anti-CCL18 antibodies were used. Due to the viscosity of the
synovial fluid the samples were diluted in PBS, containing 0.1%
Triton-X-100. The dilution of each sample was preformed accord-
ing to the concentration of CCL18 in the synovial fluid determined
by Luminex analysis using the Custom Human 27-Plex Cytokine
Panel according to the manufacturer’s instructions. The synovial
fluid samples were diluted to load a final amount of 1 ng CCL18
on the RS100 ProteinChip.
SIZE EXCLUSION CHROMATOGRAPHY
Complex formation of CCL18 with Evasin-1, -3, and -4 was
analyzed by size exclusion chromatography (SEC). Five hun-
dred micrograms of CCL18 and an equimolar amount of the
Evasins and were incubated for 45 min at RT in PBS and then
applied to a Superdex75 column, previously equilibrated with PBS
and calibrated with the following proteins: conalbumin, 75 kDa;
ovalbumin, 44 kDa; carbonic anhydrase, 29 kDa; ribonuclease A,
13.7 kDa, and aprotinin, 6.5 kDa. Fractions were eluted at a flow
rate of 1.5 ml/min and were subsequently analyzed on silver
stained sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) gels.
NEUTRALIZATION OF BIOACTIVITY
Inhibition of 125I-CCL18 binding to PBLs by the Evasins was
assessed as described above. Neutralization of inhibition by CCL18
of CCL11 induced chemotaxis was performed using the EC80
(the concentration of CCL11, producing 80% of the maximal
migration) and the CCL18 at a concentration at which a max-
imal inhibitory effect was observed. The neutralizing activity of
the Evasins was tested by incubating serial dilutions to cover a
range from 10−11 to 20−6 M. CCL11, CCL18, and the Evasins were
placed in the lower chamber of the chemotaxis plate in triplicate.
The conditions for the assay were used as described above.
DETERMINATION OF mRNA LEVELS BY QUANTITATIVE PCR
Total RNA was isolated from the cells of interest using a RNeasy
microkit (Qiagen) and reverse-transcribed using a iScript cDNA
Synthesis Kit (BioRad). The cDNA quality control was performed
by the amplification of the housekeeping gene (HKG) glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH). The PCR reaction
was performed using the Platinum Blue PCR SuperMix and the
GAPDH_forward 5′-CTG CAC CAC CAA CTG CTT AG and
reverse primer GAPDH_reverse 5′-CCA GTG AGC TTC CCG
TTC AG according to the manufacturer’s instructions. The ampli-
fied PCR products were analyzed by agarose gel electrophoresis
using a 1.1% agarose gel. Quantitative real time PCR was per-
formed using a QuantiFast SYBR green PCR kit (Roche) accord-
ing to the manufacturer’s instructions and PCR products were
detected using an ABI PRISM 7900HT sequence detection sys-
tem instrument (Applied Biosystems). Validated primer pairs
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were used to amplify PITPNM3/Nir1 (QT00493675) from Qiagen.
GAPDH (QT01192646), actin (QT01680476), and 18S ribosomal
RNA (18S rRNA) (QT00199367) expression was used as HKGs.
The SDS 2.2.2 software system (Applied Biosystems) was used
to analyze the expression levels of the target genes. The rela-
tive expression of the target gene PITPNM3 was quantified in
relation to the HKGs GAPDH, actin, and 18S rRNA. The rel-
ative quantification ratios (R) were calculated in % of HKG
using the following equation, in which an optimal doubling of
the target DNA during each performed PCR cycle is assumed:
R= 100/2 (CtPITPNM3−Ct HKG).
CHEMOKINE BINDING ASSAY TO IMMOBILIZED HEPARIN
To test the ability of CCL18 and 44AAGA47-CCL18 for their
heparin binding ability a colorimetric enzyme-linked immunosor-
bent assay was performed as previously described using polyclonal
anti-CCL18 antibodies (20). For detection a secondary anti-
body solution (donkey anti-goat IgG-HRP antibody) at 1:10,000
was used.
RESULTS
CHEMOTACTIC RESPONSES INDUCED BY CCL18
Chemotactic responses of purified leukocyte subpopulations
(CD4+ T lymphocytes, CD8+ T lymphocytes, B lymphocytes,
and NK cells) towards CCL18 displayed bell-shape curves with
a maximal response induced by 10–100 nM CCL18 (Figure 1).
The chemotactic index was generally approximately 0.5, although
a chemotactic index of 3 was sometimes achieved whilst cells
from other donors showed almost no response. The chemotactic
responses induced by CCL18 are weak compared to the lympho-
cyte chemoattractants CXCL12α, CXCL13, and CX3CL1, which
were used as positive controls for T lymphocytes, B lympho-
cytes, and NK cells, respectively. CXCL12α induced a chemotactic
response of T lymphocytes with a chemotactic index between 3
and 6 (Figures 1A,B, lefts panels). A chemotactic index around
3 was obtained for NK cells migrating to CX3CL1 (Figure 1C,
left panel) and B lymphocytes showed a chemotactic response to
CXCL13 with a chemotactic index of 12.5 (Figure 1D, left panel).
The chemotactic response of freshly isolated monocytes, as well
as monocytes cultured between 1 and 4 days as described (25),
towards CCL18 was tested. No chemotactic response of freshly
isolated or cultured monocytes to CCL18 was obtained (data not
shown). Similarly no chemotactic response of the monocytic cell
line THP1, nor of the T cell lines, MOLT4, and Jurkat to CCL18
was observed (data not shown).
Based on our results PBL, comprising T lymphocytes, B lym-
phocytes, and NK cells, compose the leukocyte subpopulations
responding to CCL18 and were used in most of the following
experiments.
INVESTIGATION OF SIGNAL TRANSDUCTION PATHWAYS INDUCED BY
CCL18
We tested whether the chemotactic responses induced by CCL18
are Giα protein mediated as previously reported (10, 13) by pre-
treatment of the cells with PTX, which is a broad inhibitor of Gi
protein-coupled receptors. This resulted in the complete abroga-
tion in chemotactic responses of the cells to CCL18 (Figure 2A,
upper panel), indicating a G-protein-coupled receptor-mediated
event. The chemotaxis induced by CXCL12α and the influence of
PTX were used as a positive control (Figure 2A, lower panel). Cell
viability was determined by flow cytometry upon PTX-treatment
of the cells using Propidium iodide. No discrepancy in cell viability
was observed between PTX-treated and untreated cells (data not
shown).
Next we investigated the ability of CCL18 to induce extra-
cellular signal-regulated kinase (ERK)-1/2 phosphorylation in T
lymphocytes, as the activation of the ERK-1/2 signaling pathway
is known to be involved in some chemokine induced responses
(26, 27). T lymphocytes were stimulated with 100 nM CCL18, and
CXCL12α was again used as a positive control. A time course was
performed ranging from 15 s to 5 min of stimulation. CXCL12α
induced ERK-1/2 phosphorylation at all time points tested. How-
ever the stimulation with CCL18 did not result in ERK-1/2 phos-
phorylation at any time point (Figure 2B). The ERK-1/2 phos-
phorylation in CD4+ and CD8+ T lymphocytes was tested using
different concentrations of CCL18 (10, 50, 100, and 1µM) and a
broader time course ranging from 15 s to 15 min. However at all
concentrations of CCL18 and at all time points no induction of
ERK-1/2 phosphorylation was detected (data not shown).
We then investigated whether CCL18 induces other signaling
pathways such as that which is required for receptor internaliza-
tion. CCL18 has been reported to bind, and antagonize CCR3 (7),
so we addressed the question of whether it was able to induce the
signaling pathways for receptor internalization. Receptor internal-
ization studies were performed using freshly isolated eosinophils,
on which CCR3 has been described to be the major chemokine
receptor. The down-modulation of the CCR3 surface expression
as determined by flow cytometry analysis upon the exposure of
eosinophils with CCL5 and CCL11 was used as a positive control
(22). The exposure of eosinophils to CCL5 caused a reduction
of CCR3 receptor surface expression of 56.1 and 38.03%, and
CCL11 caused CCR3 internalization of 72.7 and 69.8% after 15
and 60 min, respectively. However there was no reduction in CCR3
surface expression observed after the exposure of eosinophils to
CCL18 (12.5 or 125 nM) after 15 or 60 min, indicating that CCL18
does not trigger the signaling pathways to induce this activity
(Figure 2C).
We then investigated whether CCL18 exhibits mitogenic activ-
ity inducing cell proliferation. T lymphocytes were stimulated by
mimicking the binding of antigen presenting cells using anti-CD3
and anti-CD28 antibodies for 72 h. In order to investigate the
mitogenic activity of CCL18 on T lymphocyte proliferation the
cells were stimulated with increasing concentrations of CCL18
in the presence or absence of anti-CD3 and anti-CD28 antibod-
ies. The quantification of cell proliferation was estimated based
on the number of cell division using CFSE and flow cytometry
assessment. Figure 2D shows an increase in T lymphocyte pro-
liferation in response to CD3/CD28 costimulation, but no effect
on T lymphocyte proliferation was observed upon stimulation
with CCL18.
CHARACTERIZATION OF∆2- AND∆3-CCL18
Since N-terminal processed forms of CCL18 have previously
been identified from the conditioned medium of PBMC (16),
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FIGURE 1 | In vitro chemotactic responses of lymphocyte
subpopulations to CCL18. Chemotactic responses of (A) CD4+ T
lymphocytes, (B) CD8+ T lymphocytes, (C) NK cells, and (D) B
lymphocytes induced by CCL18 (◦) or mediated by potent receptor
agonists. (A,B) CXCL12α, (C) extracellular domain of CX3CL1, and (D)
CXCL13. Medium was used as a control (∆). Increase in scale and
exclusion of chemotactic response induced by the potent receptor
agonists (right panel). Data are expressed as chemotaxis index±SEM.
Data points are in triplicate. One out of two independent experiments is
shown.
but had not been biologically characterized, we produced these
truncated forms in order to determine potential differences in
biological activity. Equilibrium competition binding assays were
performed on PBL using 125I-CCL18 as tracer. CCL18 and
CCL18-6His competed for 125I-CCL18 binding to PBL with
IC50 values of 6.44 and 7.89 nM, respectively. The IC50 for
∆2-CCL18-6His was 1.14 nM and for ∆3-CCL18-6His 9.04 nM.
Thus similar potencies were obtained for the CCL18 trun-
cated forms demonstrating no significant difference in recep-
tor binding affinity (Figure 3A). The lack of impact on activ-
ity by these two truncations was confirmed by chemotaxis
assays, where the chemotactic responses for the ∆2- and ∆3-
CCL18-6His forms were similar to the full-length CCL18 protein
(Figure 3B).
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FIGURE 2 | Ability of CCL18 to induce signal transduction pathways
and influence cell proliferation. One out of three independent
experiments from separate donors is shown. (A) In vitro chemotactic
responses of PBL mediated by CCL18 imply Giα-protein-coupled signal
transduction mechanism. Chemotactic responses of PBL induced by
CCL18 (◦). Influence of PTX (200 ng/ml) on CCL18-mediated (•)
chemotactic responses (upper panel). Chemotactic response mediated by
CXCL12α (♦) and influence of PTX on CXCL12α-mediated responses ()
(lower panel). Medium was used as a control (∆). Data are expressed as
chemotaxis index±SEM. Data points are in triplicate. (B) ERK-1/2
phosphorylation analysis in T lymphocytes after stimulation with CCL18.
Western Blot analysis using an anti-phosphor p44/42 MAPK (ERK-1/2)
antibody. Time course for ERK-1/2 phosphorylation in T lymphocytes
stimulated with 100 nM CCL18 or CXCL12α. Detection of actin was used
as a loading control. (C) CCR3 cell surface expression after CCL18
stimulation of human eosinophils. Human eosinophils were stimulated
with 12.5 nM CCL18 (◦), CCL5 (N), CCL11 (∆), or 125 nM CCL18 (•) for 15
or 60 min. Ligand-induced CCR3 internalization was measured by Flow
cytometry. Surface expression of CCR3 was compared with CCR3
expression of unstimulated eosinophils. Results are expressed in % of
CCR3 surface expression. (D) T lymphocyte proliferation analysis after
CCL18 stimulation. T lymphocytes were stimulated or not with
anti-CD3/CD28 antibodies in the presence or absence of an increasing
concentration of CCL18 (1 nM, 10 nM, 100 nM, or 1µM). The division of
cells was measured by CFSE and flow cytometry. Data points are in
triplicate. Data are expressed in % of divided cells±SEM.
SELDI-TOF MS ANALYSIS OF CCL18 EXPRESSION
In order to identify whether other truncated forms of CCL18 exist
during inflammation we isolated CCL18 from the synovial fluid of
rheumatoid arthritis (RA) patients using SELDI-TOF MS. Initially
the integrity of recombinant CCL18 protein samples was verified
on the NP20 ProteinChip. CCL18 was intact with a mass-to-charge
ratio (m/z) of 7834.3 (MWtheo 7851.19 Da) (Figure 4A). In paral-
lel to the SELDI-TOF MS analyses the mass of recombinant CCL18
was also analyzed by Matrix-assisted laser desorption/ionization
time of flight mass spectrometry (MALDI-TOF MS). A mass of
7850.80 Da was obtained, almost identical to the theoretical mol-
ecular weight of CCL18 (data not shown). This difference in mass
observed between the two mass spectroscopic technologies was
consistently observed and is due to the lower resolution and mass
accuracy with SELDI-TOF MS. This lower accuracy in the deter-
mination of the molecular mass might be due to a short time of
flight resulting in a less precise molecular weight determination.
In addition to the peak corresponding to full length CCL18 a sec-
ond, non-identified peak with a m/z of 8071.7 was observed, thus
237.4 Da higher, and which was present in all subsequent analyses.
To detect truncated forms of CCL18 in biological fluids affinity
capture by polyclonal anti-CCL18 antibodies is required. Poly-
clonal anti-CCL18 antibodies were immobilized on a RS100
Protein Chip by the covalent binding to pre-activated carbonyl
diimidazole functional groups on the chip. After the unreacted
groups were blocked with ethanolamine, the ProteinChip spots
were incubated with dilutions of recombinant CCL18 ranging
from 0.15 to 10 ng in order to determine the detection limit of
CCL18 (Figure 4B). CCL18 was detected with an average m/z of
7833± 1.45, corresponding to the mass obtained by the analysis of
recombinant CCL18 on NP20 ProteinChips. The signal intensity
correlates to the amount of recombinant CCL18 and demon-
strated a limit of detection at 0.31 ng (3.1 ng/ml) (Figure 4C).
The peak height correlating to the amount of recombinant CCL18
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FIGURE 3 | Characterization of ∆2-CCL18 and ∆3-CCL18. (A) Equilibrium
competition binding assay using 125I-CCL18 on PBL. Binding of 125I-CCL18 was
competed using an increasing concentration of CCL18 (IC50: 6.44 nM),
CCL18-6His (IC50: 7.89 nM), ∆2-CCL18-6His (IC50: 1.14 nM), ∆3-CCL18-6His
(IC50: 9.04 nM) with equal potency. Data are expressed in cpm±SEM. Data
points are in triplicate. The graph represents a single experiment. (B) In vitro
chemotactic response of PBL to CCL18 and the N-terminal truncated forms
∆2-CCL18-6His and ∆3-CCL18-6His. Medium (∆) was used as a control. Data
are expressed as chemotaxis index±SEM. Data points are in triplicate. One
representative experiment out of three is shown.
is shown in Figure 4D. In all analyses a mass 8049± 7.28 was
obtained, corresponding to the non-identified mass previously
observed (Figure 4A).
In order to detect CCL18 using the SELDI-TOF MS analysis a
sufficient amount of CCL18 present in the synovial fluid needed
to be ensured. Therefore CCL18 levels were determined in the syn-
ovial fluid samples by Luminex analyses (data not shown). CCL18
was one of the most abundant chemokines in the synovial fluid
among different chemokines measured (A. Garin et al., manu-
script in preparation). The level of CCL18 in the synovial fluid
samples of RA patients was 574.9± 109 ng/ml (n= 21). In the
synovial fluid samples of Osteoarthritis (OA) patients CCL18 lev-
els of 307± 92.5 ng/ml (n= 6) were detected. Thus the amounts
of CCL18 in the samples of RA patients was about twofold higher
than the levels found in samples of OA patients. These analy-
ses revealed that the amount of CCL18 in the synovial fluid is
sufficient for the detection by SELDI-TOF MS analysis.
Since synovial fluid is particularly viscous the samples were
diluted to a CCL18 concentration of 10 ng/ml, allowing each spot
to be incubated with synovial fluid containing a final amount
of 1 ng CCL18. Some samples were measured in duplicate if the
amount of sample was sufficient. The differences in the m/z val-
ues of each protein signal were compared to full length CCL18
within one sample (∆ to full length CCL18). The samples of four
RA and OA patients were analyzed and the mass values of the
protein-signals obtained from the SELDI-spectra are summarized
in Table 1.
The spectra revealed a major peak with an average of
7827± 4.05 Da (Figure 4E) corresponding to the mass obtained
for recombinant CCL18. A second peak approximately 200 Da
higher than that of CCL18, with an average of 8034± 3.47 Da
was detected in all synovial fluids tested. This peak correlates to
the non-identified peak, which was also observed using recom-
binant CCL18 (Figure 4A). An additional peak with an average
in molecular weight of 7765± 4.1 with a 10-fold lower signal
intensity was detected in all synovial fluids tested. This peak
revealed a molecular weight of 71 Da less than full length CCL18,
corresponding to the theoretical mass of CCL18 lacking an alanine
residue. As CCL18 has an alanine residue at both N- and C-termini
the truncation could be at either position. In the synovial fluid
samples of two RA patients (sample number: 8 and 402) a second
truncated form, with an average mass off 7638± 12.16 thus lacking
approximately 189 Da was detected (Figure 4E), corresponding to
the mass of an alanine-asparagine dipeptide of 185.19 Da. Thus
this corresponds to the truncated form of CCL18 lacking the C-
terminal dipeptide, suggesting that the 70-Da truncation occurs
at the C-terminus. Interestingly an additional peak with an aver-
age of 7997± 1.53 Da was observed in three out of four synovial
fluid samples tested from OA patients (Figure 4E, sample number
1573). It is highly unlikely that CCL18 is posttranslationally gly-
cosylated, as there are no predicted N- and O-glycosylation sites.
However as the principal intention of the SELDI-TOF MS analysis
was the identification of putative N-terminal truncated forms of
CCL18 with increased potency, no further investigations regard-
ing the observed modified forms were undertaken, and the nature
of this modification remains to be elucidated. Lastly, besides dif-
ferences in the masses, the intensity of the protein-signal allows a
comparison of the protein levels. The signal intensity of full length
CCL18 was predominant in all the synovial fluid samples tested,
indicating that this form is the biologically relevant species.
THE TICK CKBPs EVASIN-1 AND -4 BIND CCL18
An interaction of CCL18 with Evasin-1 (19) and -4 (28) has been
shown using the surface plasmon resonance method. In order
to confirm this interaction Dot-Blot and SEC analyses were per-
formed. Dot-Blot analyses were positive for Evasin-1 and -4, but
negative for Evasin-3 as expected, thereby providing a second line
of evidence that these CkBPs do bind CCL18 (data not shown).
The complex formation was further assessed by analyzing the
elution profiles of CCL18 incubated with an equimolar amount
of the Evasins by SEC. As shown in Figure 5, CCL18 eluted at
a volume corresponding to a monomeric topology. The discrep-
ancy in the theoretical masses and those determined by SEC for
Evasin-1 (Figure 5A) and -4 (Figure 5B) is due to the glycosylation
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FIGURE 4 | Detection and identification of processed CCL18 isoforms in
the synovial fluid of RA and OA patients by SELDI-TOF MS. (A) MS
spectra of recombinant CCL18 determined using NP20 ProteinChips.
Recombinant CCL18 (100 ng) was applied onto a NP20 ProteinChip Array and
mass analyses were performed by SELDI-TOF MS. (B) Standard curve of
recombinant CCL18 with RS100 ProteinChips. Dilutions of recombinant
CCL18 ranging from 0.15 to 10 ng were applied onto RS100 ProteinChip
Arrays containing immobilized polyclonal anti-CCL18 antibodies. (C) Increase
in scale at 0.31 ng. (D) Peak height displayed according to amount of
recombinant CCL18. (E) RS100 ProteinChips were coated with polyclonal
anti-human CCL18 antibodies and incubated with synovial fluid from RA
(Sample number 402 and 8) or OA (Sample number 1573) patients. Mass
spectra were generated by SELDI-TOF MS. Spectra are representative for
four RA and OA patient samples analyzed.
of the proteins and possibly to non-spherical structures. After the
injection of the Evasin-1/CCL18 (Figure 5A) and Evasin-4/CCL18
(Figure 5B) complexes the proteins co-eluted in a single peak with
an elution volume corresponding to molecular masses of 25,600
and 54,600 Da, respectively, indicating a 1:1 stoichiometry of the
complex.
The presence of the two proteins in the peak was confirmed by
SDS-PAGE analysis (Figures 5A,B, right panels). On the contrary,
and again as expected, the mixture of Evasin-3 and CCL18 eluted
as two discrete peaks at the same volume as for the individual pro-
teins (Figure 5C). This biochemical analysis again confirmed the
selective binding of CCL18 by Evasin-1 and -4.
The relevance of this interaction was then assessed by the ability
of Evasin-1 and -4 to compete for 125I-CCL18 binding to CCR3
(Figure 6A). The binding of 125I-CCL18 to CCR3 was inhibited
by Evasin-1 and -4 with IC50 values of 9.92± 1.98 nM (n= 2)
and 0.015± 0.02 nM (n= 2), respectively. Again, Evasin-3 did not
inhibit 125I-CCL18 binding to CCR3 (Figure 6A). The neutraliza-
tion ability of this interaction was corroborated by the abolition
of the inhibition of CCR3-mediated responses by CCL18 (7, 29).
CCL18 inhibits the chemotactic response of L1.2/CCR3 transfec-
tants induced by 1 nM CCL11 with an IC50 of 317.6± 48.77 nM
(n= 7), and this inhibition is abrogated in the presence of Evasin-
1 (Figure 6B). The inhibitory effect of 1 µM CCL18 which
completely inhibits migration to CCL11 was neutralized in the
presence of ≥1µM Evasin-1 (data not shown). A constant dose
of 1 nM CCL11 was then incubated with an increasing concen-
tration of CCL18 or CCL18 previously incubated with a twofold
molar excess of Evasin-1 or -3 (Figure 6B). Evasin-1 completely
abrogated the antagonistic effect of CCL18. Evasin-3 did not
show any effect on the antagonistic activity of CCL18 [IC50:
446.5± 105 nM (n= 3)]. Evasin-4 could not be analyzed in this
experiment since it inhibits the response directly by binding
CCL11.
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Table 1 | Summary of the mass detected in the synovial fluid samples of RA and OA patients by SELDI-TOF MS.
Sample number ng/ml MW (Da) ∆To full length CCL18
RHEUMATOID ARTHRITIS PATIENTS
8 41.1 7644.0+H 7614.5+H −185.4 −185.3
7760.7+H 7729.6+H −68.7 −70.2
7829.4+H 7799.8+H
8036.9+H 8011.3+H +207.5 +211.5
385 389.5 7764.6+H 7766.5+H −69.8 −73.0
7834.4+H 7839.5+H
8041.2+H 8046.0+H +206.8 +206.5
402 92.01 7655.3 +H −179.9
7765.9+H 7766.3+H −69.3 −72.2
7835.2+H 7838.5+H
8040.8+H 8043.9+H +205.6 +205.4
2282 609.7 7747.9+H 7739.8+H −72.4 −71.8
7820.3+H 7811.6+H
8029.1+H 8026.9+H +208.8 +215.3
OSTEOARTHRITIS PATIENTS
669 54.0 7766.6+H 7765.5+H −71.3 −71.2
7837.9+H 7836.7+H
8001.6+H 7999.5+H +163.7 +162.8
8046.6+H 8042.8+H +208.7 +206.1
1201 58.7 7761.0+H 7761.9+H −70.6 −70.1
7831.6+H 7832.0+H
7993.1+H 7994.9+H +161.5 +162.9
8034.7+H 8036.7+H +203.1 +204.7
1573 37.0 7762.7+H −71.6
7834.3+H
7996.9+H +162.6
8040.6+H +206.3
2076 591.0 7719.5+H −72.4
7791.9+H
8002.9+H +211.0
The concentration of CCL18 in each sample is indicated in ng/ml, as well as the mass obtained from each sample [MW (Da)] and the discrepancy of mass to full
length CCL18 which is highlighted in bold (∆ to full length CCL18).
ANALYSIS OF PITPNM3/Nir1 EXPRESSION IN LEUKOCYTES
PITPNM3/Nir1 was recently described to be a signaling recep-
tor for CCL18 on breast cancer cells (8). Therefore we aimed
to investigate whether PITPNM3/Nir1 is responsible for CCL18-
dependent responses on leukocytes. The mRNA expression level
of PITPNM3/Nir1 was determined by quantitative PCR (qPCR)
analysis from different cell subpopulations: B lymphocytes, naïve
B lymphocytes, T lymphocytes, CD8+ T lymphocytes, naïve CD4+
T lymphocytes, Monocytes, and NK cells. Universal Human Ref-
erence RNA was used as a positive control for the detection of
PITPNM3/Nir1 mRNA expression. The mRNA expression levels
were quantified against the HKGs GAPDH, actin, and 18S rRNA.
PITPNM3/Nir1 mRNA was detected in the Universal Human Ref-
erence RNA control, whereas no expression of PITPNM3/Nir1
mRNA was observed in the various cell subpopulations tested
(data not shown).
In order to determine if PITPNM3/Nir1 mediates CCL18
induced cell migration an enrichment of PITPNM3/Nir1 express-
ing cells would be obtained upon migration to CCL18. Thus we
then assessed the PITPNM3/Nir1 mRNA expression level in PBL
upon migration to CCL18 in two separate experiments. Chemo-
taxis assays were performed using PBL migrating to 10 nM CCL18,
following subsequent isolation of total RNA and qPCR analysis
were performed (Figure 7). As described above the mRNA expres-
sion levels were quantified against the HKGs GAPDH, actin, and
18S rRNA. The PITPNM3/Nir1 expression level of the cells upon
migration to CCL18 was compared to the expression level in the
cell population of origin as well as in cells upon migration to 10 nM
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FIGURE 5 | Analysis of complex formation of Evasin-1, -3, and -4
with CCL18 by SEC. CCL18 was incubated with an equimolar amount
of (A) Evasin-1, (B) -4, and (C) -3 and injected onto an analytical
Superdex 75 Prepgrade 10/300GL Tricorn column. The elution profile of
CCL18 (blue), Evasins (green), and the mixture of CCL18 and Evasins
(red) is shown in milliabsorbance units (mAU). The elution volume and
corresponding molecular weight are indicated for each peak. The
elution volume of each protein used for calibration is indicated on the
top according to their molecular weights. (A,B) SDS-PAGE analyses
were performed with the fractions corresponding to the peak elution
fractions. SDS-PAGE stained with silver. One representative
experiment out of two is shown.
of the control chemokine CXCL12α and the cells collected in the
lower chemotaxis wells without the addition of chemokine. Total
RNA isolated from the PITPNM3/Nir1 expressing breast cancer
cell line MDA-MB-231, served as a control for the detection of
PITPNM3/Nir1 expression. In addition Universal Human Refer-
ence RNA was used as a positive control for PITPNM3/Nir1 mRNA
detection in the second experiment. PITPNM3/Nir1 expression
was not detected in PBL and no enrichment in the PITPNM3/Nir1
mRNA expression level was obtained in cells upon CCL18 migra-
tion compared to the cells migrating in response to medium alone.
A small increase in mRNA expression in cells migrating to CCL18
was apparent in the second experiment but no PITPNM3/Nir1
protein was observed by Western blot analysis using PBL pro-
tein extracts, whilst strong expression in the MDA-MB-231 cells
was observed (data not shown). This leads to the conclusion that
PITPNM3/Nir1 does not trigger CCL18-mediated chemotactic
responses of leukocytes.
EQUILIBRIUM COMPETITION BINDING ASSAY TO PBLs
In order to identify the receptors binding to CCL18 we aimed
to use an expression cloning strategy, which required an assay in
order to detect the presence or absence of the receptor(s) binding
to CCL18. Equilibrium competition binding assays were devel-
oped on PBL using 125I-CCL18. Unlabelled CCL18 displaced the
tracer with an IC50 of 61.87± 38.09 nM (n= 9) (Figure 8). How-
ever as chemokines also interact with the GAGs on the cell surface
the binding of 125I-CCL18 on PBL was competed with heparin.
An IC50 of 246.4± 89.49 nM (n= 6) was obtained. Importantly,
both CCL18 and heparin caused almost total displacement of the
bound 125I-CCL18. This demonstrated a binding capacity with
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FIGURE 6 | Evasin-1 neutralizes the antagonistic effect of CCL18 on
CCR3. (A) Equilibrium competition binding assay of 125I-CCL18 on L1.2/CCR3
transfectants using an increasing concentration of CCL11 and the
CCL18-binding proteins Evasin-1, -3, and -4. Data are expressed in
cpm±SEM. Data points are in triplicate. Inhibitory activity of CCL11 (IC50:
4.99 nM), Evasin-1 (IC50: 7.94 nM), and -4 (IC50: 0.03 nM) on 125I-CCL18 binding
to CCR3. (B) Inhibition of chemotaxis using L1.2/CCR3 transfectants.
Migration of L1.2/CCR3 transfectants to a constant concentration of 1 nM
CCL11 was inhibited by an increasing concentration of CCL18 (IC50:
556.8 nM). The effect of Evasin-1 on the antagonistic activity of CCL18 on
CCR3 was assessed by the incubation of CCL18 with a twofold access of
Evasin-1. Evasin-3 (IC50: 421 nM) was used as a control. Data are expressed as
chemotaxis index±SEM. Data points are in triplicate. One representative
experiment out of two is shown.
FIGURE 7 | Determination of the PITPNM3/Nir1 mRNA
expression level in CCL18 responsive cells. Analysis of
PITPNM3/Nir1 mRNA expression by qPCR with (A) 1.25 ng and (B)
3.13 ng cDNA per well. Universal Human Reference RNA (Control)
and MDA-MB-231 were used as positive controls. CCL18: PBL upon
migration to 10 nM CCL18; CXCL12α: PBL upon migration to 10 nM
CXCL12α and medium: PBL collected in the lower chemotaxis well
without the addition of chemokine. Data are expressed in %
expression of HKG (GAPDH, actin, 18S rRNA)±SEM. The graphs
represent a single experiment.
only fourfold difference in affinity between the CCL18-receptor
and CCL18-GAG interaction, which would not enable subsequent
screening in an expression cloning approach.
IDENTIFICATION AND CHARACTERIZATION OF THE
CCL18-GAG-BINDING EPITOPE
In order to limit binding of CCL18 to GAGs we constructed a
mutant designed to abrogate interaction with GAGs. Previous
studies on heparin binding proteins have shown that the binding
to GAGs is mediated by clusters of basic residues in the pro-
tein (30). CCL18 is a basic chemokine with an isoelectric point
of pH 9.21. The inspection of the primary structure of CCL18
exhibits two separate clusters of basic residues, 44KRGR47 and
55KKWVQK60. The first cluster is located in the 40s loop and the
second at the C-terminal region merging from the 50s loop into
the C-terminal α-helix. Since the BBXB motif is a well charac-
terized heparin binding motif, which has been previously shown
to play this role on the 40s loop of related chemokines, CCL3
(31, 32), CCL4 (33), and CCL5 (34, 35) we created the variant
44AAGA47-CCL18 (Figure 9A).
The binding of 44AAGA47-CCL18 to heparin was investigated
using heparin coated binding plates (Figure 9B). The amount
of protein bound to immobilized heparin was determined using
polyclonal anti-CCL18 antibodies. Non-specific interactions of
the proteins with the plate were determined by directly measur-
ing the interaction of the protein with the uncoated plate. The
mutant showed 85% reduction in binding capacity in compar-
ison to CCL18, confirming the involvement of the 44KRGR47
www.frontiersin.org July 2013 | Volume 4 | Article 193 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Krohn et al. CCL18 principally acts through glycosaminoglycans
cluster in GAG binding. A second analysis consisted of competition
binding assays on heparin sepharose beads with 125I-CCL18 and
125I-44AAGA47-CCL18 performed as previously described (36)
confirmed the loss of heparin binding (data not shown).
The binding capacity of the mutant was then assessed on
PBLs compared to CCL18 binding (Figure 9C). These studies
demonstrated that replacement of the basic residues by alanine
in the 40s cluster abrogates approximately 75% of the binding
capacity to PBL, suggesting either an involvement of the 44KRGR47
cluster in receptor binding, or that the majority of binding to the
cells is mediated by GAGs. However by assessing the biological
FIGURE 8 | Equilibrium competition binding assays of 125I-CCL18 on
PBL. The binding of 125I-CCL18 to PBL was competed with Heparin
(heparin-3393) (IC50: 97.43 nM) and CCL18 (IC50: 24.37 nM). Data are
expressed in cpm±SEM. Data points are in triplicate. One representative
experiment out of six is shown.
activity of 44AAGA47-CCL18 in chemotaxis assays no impaired cell
recruitment was observed compared to CCL18 (data not shown).
This indicates that the 44KRGR47 cluster mediates cell binding but
not receptor-mediated signaling.
DISCUSSION
CCL18 has the structural features of a chemokine, being an
8-kDa basic protein, with the conserved two disulfide motif,
and is proposed to have evolved as a duplication of the CCL3
gene (37). However it has several features which distinguish it
from its closely related homologues, CCL3, and CCL4. Firstly,
it only exists in primates, and has not been identified in any
other mammalian species. Second, its receptor remains elu-
sive after more than 15 years since its identification, despite the
efforts of several laboratories. Lastly, it appears to be one of the
most highly expressed chemokines, and is constitutively found
at high circulating levels, and is even further upregulated in
disease.
We report here that we find that it is a remarkably weak
chemoattractant of leukocytes comprising PBL, with chemotactic
indices rarely greater than 1.5. This could indicate either that the
CCL18 receptor is uniformly expressed at low levels among these
leukocyte populations or that only minor subpopulation of cells
are responsive to CCL18. It could possibly be due to the chemo-
taxis system we are using, a bare filter assay in 96-well plates.
Other laboratories using other chemotaxis methods have reported
higher potencies. Boyden chamber chemotaxis experiments have
been reported to induce migration with chemotactic indices of 4–
6 for tonsillar B lymphocyte (13) and T lymphocytes (12), whereas
transwell chambers gave chemotactic indices of approximately 3
for CD4+ and CD8+ T cells (10) and Th2 T cells (38). T cells in
FIGURE 9 | Identification of the BBXB GAG-binding motif in the 40s loop
of CCL18. (A) Prediction of the BBXB GAG-binding motif of CCL18 by a
sequence alignment of CCL18 with CCL3, CCL4, and CCL5. Basic residues,
which are part of the BBXB motif, are highlighted in bold and the conserved
cysteine residues in gray. (B) Comparison of the ability of CCL18 and
44AAGA47-CCL18 to bind to heparin immobilized on Epranex plates.
Immobilization of a dilution series of CCL18 and 44AAGA47-CCL18 (44AAGA47)
onto a heparin coated (+) or uncoated (−) heparin binding plate. Wells
containing no chemokine were used as a control (). Data are expressed in
optical absorbance at 450 nm. Data points are in duplicate. One
representative experiment out of three is shown. The capacity of
44AAGA47-CCL18 to bind to heparin is reduced. (C) The binding of 125I-CCL18
and 125I-44AAGA47-CCL18 (125I-44AAGA47) to PBL was competed with Heparin
(heparin-3393) and CCL18. Data points are in triplicate. The mutation of the
basic amino acids in the BBXB motif of CCL18 into alanine residues
considerably abrogates binding to PBL.
Frontiers in Immunology | Chemoattractants July 2013 | Volume 4 | Article 193 | 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Krohn et al. CCL18 principally acts through glycosaminoglycans
96-well chambers such as we have used was reported to migrate
with a chemotactic index of 2 (39). However we and others have
difficulty in reproducing robust migration although we sometimes
achieved a chemotactic index of 3, but sometimes also almost
no migration, which we attributed to donor variation. Biological
functions mediated by CCL18 have been described to be donor
dependent. It was shown that CCL18 generates adaptive regu-
latory T cells from CD4+ CD25− memory T cells, however this
regulatory effect of CCL18 on memory CD4+ T cells was lost when
the cells were derived from allergic subjects (40). A further study
showed that CCL18 may play a role in inducing and maintaining
immunological tolerance to inhaled antigens. CCL18 was shown
to generate functional tolerogenic dendritic cells able to prime
regulatory T cells in healthy subjects and again this effect was
shown to be lost in allergic subjects (41). Thus it might be hypoth-
esized that a desensitization phenomenon of the CCL18-receptor
occurs due to the increased level of CCL18 in allergic disease.
Alternatively, the low potency of CCL18 to induce chemotactic
responses might also be due to a missing component required for
biological activity, which might be present in vivo, but is lacking in
in vitro experiments. Thus it might be possible that CCL18 medi-
ates recruitment of these cell populations with higher potency
in vivo.
Another possibility exists in that a more potent form is pro-
duced by post-translational modification or enzyme cleavage,
for instance during inflammation. Small truncations at the N-
terminus apparently did not affect activity, and moreover the full
length form was shown to be predominant in the synovial fluid
of RA patients. In fact we observed C-terminal truncations, which
have been reported in ovarian carcinoma ascitic fluid (12), but
C-terminal modifications in general do not highly impact activ-
ity. During these studies, we observed a form of CCL18 that was
only seen in the synovial fluid of OA patients, and which had a
mass of approximately 160 Da higher. Several post-translational
modifications of chemokines have been reported. Examples are
glycosylation, the most common for proteins, has been described
for CCL2 (42–44), citrullination has been described for several
chemokines including CXCL8 and CXCL10 (44, 45), and nitra-
tion has been reported for CCL2 (46). However none of these
correspond to an additional mass of 160 Da, which could rep-
resent phosphorylation, although this has not yet been observed
for chemokines. However, since we were interested in identifying
more potent truncated forms, the nature of this modification and
the effect on biological activity remains to be elucidated.
Besides chemotaxis, several activities for this chemokine have
been reported, which could suggest that its primary role is not
cell recruitment. CCL18 has been reported as a profibrotic fac-
tor, which stimulates collagen production in lung and dermal
fibroblasts, whereas the effect on fibroblast proliferation was less
pronounced (47). CCL18 has also been shown to be a mat-
uration factor for monocytes inducing a pattern of cytokine
expression which resembled that of IL-4-stimulated M2-spectrum
macrophages (48). CCL18 has also been shown to generate adap-
tive regulatory T cells from CD4+ CD25− memory T cells of
healthy subjects (40). As many of the CC chemokines are known
to induce costimulatory effects on T cell proliferation (49) we were
interested to investigate the effect of CCL18. The investigation of
the role of CCL18 in T lymphocyte proliferation revealed neither
an induction of proliferation nor enhanced or reduced prolifer-
ation in response to CD3/CD28 stimulation, demonstrating no
effect of CCL18 on T lymphocyte proliferation.
It should be noted that many of these activities described for
CCL18 point to a role in dampening inflammation as opposed to it
having a pro-inflammatory activity, which is not necessarily incon-
sistent with it being upregulated during many diseases. We have in
fact observed properties which corroborate this anti-inflammatory
role, such as antagonism of certain pro-inflammatory receptors, in
addition to that of CCR3 (7) as well as its ability to displace GAG-
bound chemokines (29). If this is the case, why would ticks want
to inhibit CCL18? The fact that the tick R. sanguineus produces
two CkBPs that bind CCL18 is intriguing (19). We have asked the
question as to whether this binding is serendipitous since, first, it is
thought to have evolved as a duplication of the CCL3 gene (37) and
second, this chemokine is only expressed in primates, whereas this
tick feeds on many hosts, such as dogs, rodents, cattle, deer, and
humans (50). The biochemical and bioassays we have performed
indicate that Evasin-1 and -4 do in fact bind and neutralize CCL18,
although we did not test it as an inhibitor of chemotaxis due to
the weak activity we obtain. The fact that R. sanguieneus encodes
CCL18-binding proteins implies the relevance of this chemokine
in the human host defense and one may wonder if this has not
co-evolved with certain tick-borne parasitic diseases that occur
in man.
Despite the fact that the chemotactic effect was not dramatic,
we considered attempting to identify the elusive receptor using an
expression cloning approach from the leukocyte subsets to which
it migrated. We set up an assay to enable the identification of the
cDNA expressing the receptor during expression cloning. Using
radiolabeled CCL18 in an equilibrium competition assay to the
responding subset of leukocytes, PBL, we observed similar poten-
cies of the unlabeled chemokine and heparin in the displacement
of the tracer, indicating that the binding to these cells was largely
due to binding to GAGs. This was confirmed by the abrogation
of the GAG binding of CCL18, since the mutant 44AAGA47-
CCL18 lost the majority of its binding capacity. However the
mutant was still able to induce the, albeit weak, chemotactic
response, posing a conundrum as to the nature of the recep-
tor that it activates. This issue remains to be resolved, although
we hypothesize that receptor activation is attained through the
remaining binding capacity to PBL demonstrated by 44AAGA47-
CCL18. The substantial binding to the leukocyte cell surface must
play an important role for this chemokine which merits further
investigation.
In conclusion many facets of CCL18 biology remain to
be elucidated, in particular its receptor. The identification of
PITPNM3/Nir1 as a PTX-sensitive cell surface receptor responsi-
ble for the CCL18 induced migration of human breast cancer cells
(8) indicated that this could be the receptor for this chemokine on
leukocytes, but unfortunately we have shown that this seems not
to be the case. Further studies will be needed to fully describe the
biological relevance of this chemokine, which is the most highly
expressed member of the family, and determine if its role is actually
beyond that of cellular recruitment, unlike the other chemokines
identified to date. Lastly the question is raised as to whether it acts
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on a receptor that does not belong to the classical family of 7TM
GPCRs, or does it require hetero-dimerization of to date, uniden-
tified molecules, and does its remarkable GAG-binding capacity
play a role in receptor activation?
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